^
Association details:
Biomarker:LRP1B mutation
Cancer:Non Small Cell Lung Cancer
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Targeted sequencing analysis of predominant histological subtypes in resected stage I invasive lung adenocarcinoma.

Published date:
05/29/2020
Excerpt:
...LRP1B mutations, which has been reported to be associated with high tumor mutation burden and better response to immunotherapy, were only detected from 5 SPA patients (p = 0.001)….showed that SPA patients harboring LRP1B mutations may benefit from immunotherapy.
DOI:
10.1200/JCO.2020.38.15_suppl.e21067